Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis
Journal of Gynecologic Oncology · 2024
DOI: 10.3802/jgo.2024.35.e13 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Hao Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Exosomes, Sirtuins, Mitochondrial Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NSFC, National Natural Science Foundation of Shanghai, Clinical Project of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
OBJECTIVE: We previously elucidated that long non-coding RNA Promoter of CDKN1A Antisense DNA damage Activated RNA (PANDAR) as a p53-dependent oncogene to promote cisplatin resistance in ovarian cancer (OC). Intriguingly, high level of p53-independent PANDAR was found in cisplatin-resistant patients with p53 mutation. Here, our study probed the new roles and the underlying mechanisms of PANDAR in p53-mutant OC cisplatin-resistance. METHODS: A2780 and A2780-DDP cells were served as OC cisplatin-sensitive and cisplatin-resistant cells. HO-8910PM cells were subjected to construct chemotherapy-induced extracellular vesicles (Chemo-EVs). Transmission electron microscopy (TEM) and nanoparticle tracking analysis were employed to evaluate Chemo-EVs. Cell viability was assessed using cell counting kit-8 and colony formation assays. Cell apoptosis was assessed using Annexin V and propidium iodide staining. The relationships between PANDAR, serine and arginine-rich pre-mRNA splicing factor 9 (SRSF9) were verified by RNA immunoprecipitation and fluorescence in situ hybridization. Tumor xenograft experiment was employed to evaluate the effects of PANDAR-Chemo-EVs on OC cisplatin-resistance in vivo. Immunofluorescent staining and immunohistochemistry were performed in tumor tissue. RESULTS: PANDAR level increased in OC patients with p53-mutation. PANDAR efflux enacted via exosomes under cisplatin conditions. Additionally, exosomes from OC cell lines carried PANDAR, which significantly increased cell survival and chemoresistance in vitro and tumor progression and metastasis in vivo. During cisplatin-induced stress, SRSF9 was recruited to nuclear bodies by increased PANDAR and muted apoptosis in response to cisplatin. Besides, SRSF9 significantly increased the ratio of SIRT4/SIRT6 mRNA in OC. CONCLUSION: Cisplatin-induced exosomes transfer PANDAR and lead to a rapid adaptation of OC cell survival through accumulating SRSF9 following cisplatin stress exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Obstetrics and Gynecology, Changning Maternity and Infant Health Hospital, Shanghai, China.
- Department of Precision Research Center for Refractory Diseases, Institute for Clinical Research, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. forever_chipper@hotmail.com.
ORCID-Profile: Hao Wang, Yinuo Li, Yanan Wang, Xiumin Shang, Zhongxin Yan, Shengli Li, Wei Bao
Förderung
- NSFC
- National Natural Science Foundation of Shanghai
- Clinical Project of Shanghai Municipal Health Commission
- Foundation of Shanghai Sailing Program
- National Natural Science Foundation of China
Zitieren
APA
Wang, H., Li, Y., Wang, Y., Shang, X., Yan, Z., Li, S., & Bao, W. (2024). Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e13
Vancouver
Wang H, Li Y, Wang Y, Shang X, Yan Z, Li S, et al. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e13
BibTeX
@article{Wang2024,
author = {Wang, Hao and Li, Yinuo and Wang, Yanan and Shang, Xiumin and Yan, Zhongxin and Li, Shengli and Bao, Wei},
title = {Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis},
journal = {Journal of Gynecologic Oncology},
year = {2024},
doi = {10.3802/jgo.2024.35.e13}
}
EUVIMED